Search

Your search keyword '"Adolfsson, Jan"' showing total 537 results
Start Over Author "Adolfsson, Jan" Publication Type Academic Journals
537 results on '"Adolfsson, Jan"'

3. The GIN-McMaster guideline tool extension for the integration of quality improvement and quality assurance in guidelines: a description of the methods for its development

Author

Piggott, Thomas, Langendam, Miranda W., Parmelli, Elena, Adolfsson, Jan, Akl, Elie A., Armstrong, David, Braithwaite, Jeffrey, Brignardello-Petersen, Romina, Brozek, Jan, Follmann, Markus, Kopp, Ina, Meerpohl, Joerg J., Neamtiu, Luciana, Nothacker, Monika, Qaseem, Amir, Rossi, Paolo Giorgi, Saz-Parkinson, Zuleika, van der Wees, Philip J., and Schünemann, Holger J.

Published
2023
Full Text
View/download PDF

6. Bringing two worlds closer together: a critical analysis of an integrated approach to guideline development and quality assurance schemes

Author

Piggott, Thomas, Langendam, Miranda, Parmelli, Elena, Adolfsson, Jan, Akl, Elie A., Armstrong, David, Braithwaite, Jeffrey, Brignardello-Petersen, Romina, Brozek, Jan, Gore-Booth, Jolanta, Follmann, Markus, Leś, Zbigniew, Meerpohl, Joerg J, Neamţiu, Luciana, Nothacker, Monika, Qaseem, Amir, Giorgi Rossi, Paolo, Saz-Parkinson, Zuleika, van der Wees, Philip, and Schünemann, Holger J.

Published
2021
Full Text
View/download PDF

10. Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.

Author

Martin, Richard M., Turner, Emma L., Young, Grace J., Metcalfe, Chris, Walsh, Eleanor I., Lane, J. Athene, Sterne, Jonathan A. C., Noble, Sian, Holding, Peter, Ben-Shlomo, Yoav, Williams, Naomi J., Pashayan, Nora, Bui, Mai Ngoc, Albertsen, Peter C., Seibert, Tyler M., Zietman, Anthony L., Oxley, Jon, Adolfsson, Jan, Mason, Malcolm D., and Davey Smith, George

Abstract

This secondary analysis of a randomized clinical trial assesses whether screening for prostate-specific antigen reduces prostate cancer mortality at 15-year follow-up. Key Points: Question: In men aged 50 to 69 years, does a single invitation for a prostate-specific antigen (PSA) screening test reduce prostate cancer mortality at 15-year follow-up compared with no invitation for testing? Findings: In this secondary analysis of a randomized clinical trial of 415 357 men aged 50 to 69 years randomized to a single invitation for PSA screening (n = 195 912) or a control group without PSA screening (n = 219 445) and followed up for a median of 15 years, risk of death from prostate cancer was lower in the group invited to screening (0.69% vs 0.78%; mean difference, 0.09%) compared with the control group. Meaning: Compared with no invitation for routine PSA testing, a single invitation for a PSA screening test reduced prostate cancer mortality at a median follow-up of 15 years, but the absolute mortality benefit was small. Importance: The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) reported no effect of prostate-specific antigen (PSA) screening on prostate cancer mortality at a median 10-year follow-up (primary outcome), but the long-term effects of PSA screening on prostate cancer mortality remain unclear. Objective: To evaluate the effect of a single invitation for PSA screening on prostate cancer–specific mortality at a median 15-year follow-up compared with no invitation for screening. Design, Setting, and Participants: This secondary analysis of the CAP randomized clinical trial included men aged 50 to 69 years identified at 573 primary care practices in England and Wales. Primary care practices were randomized between September 25, 2001, and August 24, 2007, and men were enrolled between January 8, 2002, and January 20, 2009. Follow-up was completed on March 31, 2021. Intervention: Men received a single invitation for a PSA screening test with subsequent diagnostic tests if the PSA level was 3.0 ng/mL or higher. The control group received standard practice (no invitation). Main Outcomes and Measures: The primary outcome was reported previously. Of 8 prespecified secondary outcomes, results of 4 were reported previously. The 4 remaining prespecified secondary outcomes at 15-year follow-up were prostate cancer–specific mortality, all-cause mortality, and prostate cancer stage and Gleason grade at diagnosis. Results: Of 415 357 eligible men (mean [SD] age, 59.0 [5.6] years), 98% were included in these analyses. Overall, 12 013 and 12 958 men with a prostate cancer diagnosis were in the intervention and control groups, respectively (15-year cumulative risk, 7.08% [95% CI, 6.95%-7.21%] and 6.94% [95% CI, 6.82%-7.06%], respectively). At a median 15-year follow-up, 1199 men in the intervention group (0.69% [95% CI, 0.65%-0.73%]) and 1451 men in the control group (0.78% [95% CI, 0.73%-0.82%]) died of prostate cancer (rate ratio [RR], 0.92 [95% CI, 0.85-0.99]; P =.03). Compared with the control, the PSA screening intervention increased detection of low-grade (Gleason score [GS] ≤6: 2.2% vs 1.6%; P <.001) and localized (T1/T2: 3.6% vs 3.1%; P <.001) disease but not intermediate (GS of 7), high-grade (GS ≥8), locally advanced (T3), or distally advanced (T4/N1/M1) tumors. There were 45 084 all-cause deaths in the intervention group (23.2% [95% CI, 23.0%-23.4%]) and 50 336 deaths in the control group (23.3% [95% CI, 23.1%-23.5%]) (RR, 0.97 [95% CI, 0.94-1.01]; P =.11). Eight of the prostate cancer deaths in the intervention group (0.7%) and 7 deaths in the control group (0.5%) were related to a diagnostic biopsy or prostate cancer treatment. Conclusions and Relevance: In this secondary analysis of a randomized clinical trial, a single invitation for PSA screening compared with standard practice without routine screening reduced prostate cancer deaths at a median follow-up of 15 years. However, the absolute reduction in deaths was small. Trial Registration: isrctn.org Identifier: ISRCTN92187251 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. A systematic review of hormone treatment for children with gender dysphoria and recommendations for research.

Author

Ludvigsson, Jonas F., Adolfsson, Jan, Höistad, Malin, Rydelius, Per‐Anders, Kriström, Berit, and Landén, Mikael

Subjects
*GENDER dysphoria, *BONE health, *BONE density, *GONADOTROPIN releasing hormone, *RANDOMIZED controlled trials
Abstract

Aim: The aim of this systematic review was to assess the effects on psychosocial and mental health, cognition, body composition, and metabolic markers of hormone treatment in children with gender dysphoria. Methods: Systematic review essentially follows PRISMA. We searched PubMed, EMBASE and thirteen other databases until 9 November 2021 for English‐language studies of hormone therapy in children with gender dysphoria. Of 9934 potential studies identified with abstracts reviewed, 195 were assessed in full text, and 24 were relevant. Results: In 21 studies, adolescents were given gonadotropin‐releasing hormone analogues (GnRHa) treatment. In three studies, cross‐sex hormone treatment (CSHT) was given without previous GnRHa treatment. No randomised controlled trials were identified. The few longitudinal observational studies were hampered by small numbers and high attrition rates. Hence, the long‐term effects of hormone therapy on psychosocial health could not be evaluated. Concerning bone health, GnRHa treatment delays bone maturation and bone mineral density gain, which, however, was found to partially recover during CSHT when studied at age 22 years. Conclusion: Evidence to assess the effects of hormone treatment on the above fields in children with gender dysphoria is insufficient. To improve future research, we present the GENDHOR checklist, a checklist for studies in gender dysphoria. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Use of Antiepileptic Drugs and Risk of Prostate Cancer: A Nationwide Case-Control Study in Prostate Cancer Data Base Sweden.

Author

George, Gincy, Garmo, Hans, Adolfsson, Jan, Elf, Kristin, Gedeborg, Rolf, Holmberg, Lars, Stattin, Pär, Styrke, Johan, and Van Hemelrijck, Mieke

Subjects
ANTICONVULSANTS, LENGTH of stay in hospitals, CONFIDENCE intervals, MULTIPLE regression analysis, CASE-control method, COMPARATIVE studies, DESCRIPTIVE statistics, RESEARCH funding, ODDS ratio, PROSTATE tumors, DISEASE risk factors
Abstract

An inverse association between use of antiepileptic drugs (AEDs) and prostate cancer (PCa) has been suggested, putatively due to the histone deacetylases inhibitory (HDACi) properties of the AEDs. In a case-control study in Prostate Cancer data Base Sweden (PCBaSe), PCa cases diagnosed between 2014 and 2016 were matched to five controls by year of birth and county of residence. AED prescriptions were identified in the Prescribed Drug Registry. Odds ratios (ORs) and 95% confidence intervals for risk of PCa were estimated using multivariable conditional logistic regression, adjusted for civil status, education level, Charlson comorbidity index, number of outpatient visits, and cumulative duration of hospital stay. Dose responses in different PCa risk categories and HDACi properties of specific AED substances were further explored. 1738/31591 (5.5%) cases and 9674/156802 (6.2%) controls had been exposed to AED. Overall, users of any AED had a reduced risk of PCa as compared to nonusers (OR: 0.92; 95% CI: 0.87–0.97) which was attenuated by adjustment to healthcare utilisation. A reduced risk was also observed in all models for high-risk or metastatic PCa in AED users compared to nonusers (OR: 0.89; 95% CI: 0.81–0.97). No significant findings were observed for dose response or HDACi analyses. Our findings suggest a weak inverse association between AED use and PCa risk, which was attenuated by adjustment for healthcare utilisation. Moreover, our study showed no consistent dose-response pattern and no support for a stronger reduction related to HDAC inhibition. Further studies focusing on advanced PCa and PCa treatments are needed to better analyse the association between use of AED and risk of PCa. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

42. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists.

Author

Bonde, Tiago M., Westerberg, Marcus, Aly, Markus, Eklund, Martin, Adolfsson, Jan, Bill-Axelson, Anna, Garmo, Hans, Stattin, Pär, and Robinson, David

Subjects
PROSTATE cancer, GONADOTROPIN releasing hormone, CASTRATION-resistant prostate cancer, PROSTATE cancer patients, PROSTATE-specific antigen
Abstract

Objectives: To predict castration-resistant prostate cancer (CRPC) and prostate cancer (Pca) death by use of clinical variables at Pca diagnosis and PSA levels after start of gonadotropin-releasing hormone agonists (GnRH) in men with non-metastatic castration sensitive prostate cancer (nmCSPC). Materials and Methods: PSA values for 1603 men with nmCSPC in the National Prostate Cancer Register of Sweden who received GnRH as primary treatment were retrieved from Uppsala-Örebro PSA Cohort and Stockholm PSA and Biopsy Register. All men had measured PSA before (pre-GnRH PSA) and 3–6 months after (post-GnRH PSA) date of start of GnRH. Unadjusted and adjusted Cox models were used to predict CRPC by PSA levels. PSA levels and ISUP grade were used to construct a risk score to stratify men by tertiles according to risk of CRPC and Pca death. Results: 788 (49%) men reached CRPC and 456 (28%) died of Pca during follow-up. Post-GnRH PSA predicted CRPC regardless of pre-GnRH PSA. CRPC risk increased with higher post-GnRH PSA, HR 4.7 (95% CI: 3.4–6.7) for PSA > 16 ng/mL vs 0–0.25 ng/mL and with ISUP grade, HR 3.7 (95%: 2.5–5.4) for ISUP 5 vs ISUP 1. Risk of Pca death in men above top vs bellow bottom tertile of post-GnRH PSA and ISUP grade was HR 4.1 (95% CI: 3.0–5.5). Conclusion: A risk score based on post-GnRH PSA and ISUP grade could be used for early identification of a target group for future clinical trials on additional therapy to GnRH. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007

Author

Walters, Sarah, Maringe, Camille, Coleman, Michel P, Peake, Michael D, Butler, John, Young, Nicholas, Bergström, Stefan, Hanna, Louise, Jakobsen, Erik, Kölbeck, Karl, Sundstrøm, Stein, Engholm, Gerda, Gavin, Anna, Gjerstorff, Marianne L, Hatcher, Juanita, Johannesen, Tom Børge, Linklater, Karen M, McGahan, Colleen E, Steward, John, Tracey, Elizabeth, Turner, Donna, Richards, Michael A, Rachet, Bernard, Brostrøm, Søren, Bryant, Heather, Currow, David, Gavin, Anna, Gunnarsson, Gunilla, Hanson, Jane, Harper, Todd, Kaasa, Stein, Richards, Michael A, Sherar, Michael, Thomas, Bob, Adolfsson, Jan, Andersen, Ole, Bryant, Heather, Coldman, Andy, Dhaliwal, Dhali, Engholm, Gerda, Gavin, Anna, Forman, David, Gjerstorff, Marianne L, Hatcher, Juanita, Hosbond, Charlotte, Johannesen, Tom B, Lambe, Mats, Linklater, Karen M, Marrett, Loraine, McGahan, Colleen E, McLaughlin, John, Meechan, David, Middleton, Richard, Milnes, Kamini, Nishri, Diane, Quin, Nicola, Rabenek, Linda, Russell, Carol, Shin, Janey, Steward, John, Tracey, Elizabeth, Turner, Donna, Bergström, Stefan, Boyer, Michael, Butler, John, Evans, William, Hanna, Louise, Jakobsen, Erik, Kölbeck, Karl, Lester, Jason, McAleese, Jonathan, Peake, Michael D, Sundstrøm, Stein, Young, Nicholas, Williamson, Ian, Walters, Sarah, Maringe, Camille, Coleman, Michel P, and Bernard, Rachet

Published
2013
Full Text
View/download PDF

49. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease

Author

Amin Al Olama, Ali, Kote-Jarai, Zsofia, Schumacher, Fredrick R., Wiklund, Fredrik, Berndt, Sonja I., Benlloch, Sara, Giles, Graham G., Severi, Gianluca, Neal, David E., Hamdy, Freddie C., Donovan, Jenny L., Hunter, David J., Henderson, Brian E., Thun, Michael J., Gaziano, Michael, Giovannucci, Edward L., Siddiq, Afshan, Travis, Ruth C., Cox, David G., Canzian, Federico, Riboli, Elio, Key, Timothy J., Andriole, Gerald, Albanes, Demetrius, Hayes, Richard B., Schleutker, Johanna, Auvinen, Anssi, Tammela, Teuvo L.J., Weischer, Maren, Stanford, Janet L., Ostrander, Elaine A., Cybulski, Cezary, Lubinski, Jan, Thibodeau, Stephen N., Schaid, Daniel J., Sorensen, Karina D., Batra, Jyotsna, Clements, Judith A., Chambers, Suzanne, Aitken, Joanne, Gardiner, Robert A., Maier, Christiane, Vogel, Walther, Dörk, Thilo, Brenner, Hermann, Habuchi, Tomonori, Ingles, Sue, John, Esther M., Dickinson, Joanne L., Cannon-Albright, Lisa, Teixeira, Manuel R., Kaneva, Radka, Zhang, Hong-Wei, Lu, Yong-Jie, Park, Jong Y., Cooney, Kathleen A., Muir, Kenneth R., Leongamornlert, Daniel A., Saunders, Edward, Tymrakiewicz, Malgorzata, Mahmud, Nadiya, Guy, Michelle, Govindasami, Koveela, OʼBrien, Lynne T., Wilkinson, Rosemary A., Hall, Amanda L., Sawyer, Emma J., Dadaev, Tokhir, Morrison, Jonathan, Dearnaley, David P., Horwich, Alan, Huddart, Robert A., Khoo, Vincent S., Parker, Christopher C., Van As, Nicholas, Woodhouse, Christopher J., Thompson, Alan, Dudderidge, Tim, Ogden, Chris, Cooper, Colin S., Lophatonanon, Artitaya, Southey, Melissa C., Hopper, John L., English, Dallas, Virtamo, Jarmo, Le Marchand, Loic, Campa, Daniele, Kaaks, Rudolf, Lindstrom, Sara, Diver, W. Ryan, Gapstur, Susan, Yeager, Meredith, Cox, Angela, Stern, Mariana C., Corral, Roman, Aly, Markus, Isaacs, William, Adolfsson, Jan, Xu, Jianfeng, Zheng, S. Lilly, Wahlfors, Tiina, Taari, Kimmo, Kujala, Paula, Klarskov, Peter, Nordestgaard, Børge G., Røder, M. Andreas, Frikke-Schmidt, Ruth, Bojesen, Stig E., FitzGerald, Liesel M., Kolb, Suzanne, Kwon, Erika M., Karyadi, Danielle M., Orntoft, Torben Falck, Borre, Michael, Rinckleb, Antje, Luedeke, Manuel, Herkommer, Kathleen, Meyer, Andreas, Serth, Jürgen, Marthick, James R., Patterson, Briony, Wokolorczyk, Dominika, Spurdle, Amanda, Lose, Felicity, McDonnell, Shannon K., Joshi, Amit D., Shahabi, Ahva, Pinto, Pedro, Santos, Joana, Ray, Ana, Sellers, Thomas A., Lin, Hui-Yi, Stephenson, Robert A., Teerlink, Craig, Muller, Heiko, Rothenbacher, Dietrich, Tsuchiya, Norihiko, Narita, Shintaro, Cao, Guang-Wen, Slavov, Chavdar, Mitev, Vanio, Chanock, Stephen, Gronberg, Henrik, Haiman, Christopher A., Kraft, Peter, Easton, Douglas F., and Eeles, Rosalind A.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results